Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
British Journal of Haematology
|
December 13, 2017
A retrospective study on the management of patients with rituximab refractory follicular lymphoma
Philippe Solal-Céligny, Pierre Leconte, Aurélie Bardet, et al.
Human Reproduction (Oxford, England)
|
November 16, 2007
Defining poor and optimum performance in an IVF programme
Jose A Castilla, Juana Hernandez, Yolanda Cabello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2007
Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma
Adriana Handra-Luca, Juana Hernandez, Giannis Mountzios, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
March 6, 2007
Surveillance and risk factors on hysterectomy wound infection rate in Gran Canaria, Spain
Jesús Molina-Cabrillana, Leonor Valle-Morales, Juana Hernandez-Vera, et al.
American Journal of Clinical Oncology
|
November 4, 2009
DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer
Christophe M Raynaud, Juana Hernandez, Frédérique P Llorca, et al.
Bulletin Du Cancer
|
October 9, 2014
[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]
Jean-Yves Pierga, Rémy Delva, Xavier Pivot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data
Jean-Yves Pierga, Thierry Petit, Christelle Lévy, et al.
The Lancet. Oncology
|
December 3, 2014
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
British Journal of Haematology
|
December 13, 2017
A retrospective study on the management of patients with rituximab refractory follicular lymphoma
Philippe Solal-Céligny, Pierre Leconte, Aurélie Bardet, et al.
Human Reproduction (Oxford, England)
|
November 16, 2007
Defining poor and optimum performance in an IVF programme
Jose A Castilla, Juana Hernandez, Yolanda Cabello, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2007
Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma
Adriana Handra-Luca, Juana Hernandez, Giannis Mountzios, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
March 6, 2007
Surveillance and risk factors on hysterectomy wound infection rate in Gran Canaria, Spain
Jesús Molina-Cabrillana, Leonor Valle-Morales, Juana Hernandez-Vera, et al.
American Journal of Clinical Oncology
|
November 4, 2009
DNA damage repair and telomere length in normal breast, preneoplastic lesions, and invasive cancer
Christophe M Raynaud, Juana Hernandez, Frédérique P Llorca, et al.
Bulletin Du Cancer
|
October 9, 2014
[Bevacizumab and taxanes in the first-line treatment of metastatic breast cancer : overall survival and subgroup analyses of the ATHENA study in France]
Jean-Yves Pierga, Rémy Delva, Xavier Pivot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 25, 2014
Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data
Jean-Yves Pierga, Thierry Petit, Christelle Lévy, et al.
The Lancet. Oncology
|
December 3, 2014
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial
Bruno Coudert, Jean-Yves Pierga, Marie-Ange Mouret-Reynier, et al.
Page
of 1